Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer.

Identification of secreted proteins of lung cancer could provide new candidates of serum biomarkers for cancer diagnosis and prognosis evaluation. In this study, non-small cell lung cancer (NSCLC) cell line A549 was cultured. Proteins in the conditioned medium of A549 were recovered and the proteome analysis was subsequently performed. Secreted proteins of A549 were identified using mass spectrometry and database search. Fourteen human proteins were identified, including peptidyl-prolyl cis-trans isomerase A, manganese superoxide dismutase, peroxiredoxin 1, phosphatidylethanolamine-binding protein, glutathione S-transferase P, PGP9.5, alpha enolase, phosphoglycerate mutase 1, galectin-1 and dihydrodiol dehydrogenase (DDH). DDH was selected for further analysis using RT-PCR, immunoblotting, immunohistochemical staining and ELISA in NSCLC patients. Compared with normal lung tissues, higher DDH mRNA and protein expression level were found in 15 NSCLC cancer tissues (p<0.05). DDH overexpression was identified to be located in cytoplasm and cell membrane by immunohistochemical staining in NSCLC tissue. The serum level of DDH was significantly higher in NSCLC patients (n=64) than nonmalignant lung tumor (n=20) and healthy controls (n=20) (p<0.05). The results show that DDH was one of the secreted proteins in NSCLC. It can serve as a tissue marker and a novel serological marker of NSCLC. Identification of secreted proteins could be a feasible and effective strategy to search potential serum biomarkers of cancer.

[1]  Michael J Campa,et al.  Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. , 2003, Cancer research.

[2]  S. Goodman,et al.  PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. , 1999, The American journal of pathology.

[3]  E. Eigenbrodt,et al.  Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. , 2000, Anticancer research.

[4]  Michael E. Burczynski,et al.  Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones , 2000 .

[5]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[6]  Kai-Ping Chang,et al.  Cancer cell‐secreted proteomes as a basis for searching potential tumor markers: Nasopharyngeal carcinoma as a model , 2005, Proteomics.

[7]  J. Cheville,et al.  Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  O. Jensen,et al.  A proteome study of secreted prostatic factors affecting osteoblastic activity: identification and characterisation of cyclophilin A. , 2003, European journal of cancer.

[9]  Tzei-Yi Lin,et al.  Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. , 2001, Cancer research.

[10]  J. Sowadski,et al.  Prevalent overexpression of prolyl isomerase Pin1 in human cancers. , 2004, The American journal of pathology.

[11]  P. Hirvikoski,et al.  Peroxiredoxins, a novel protein family in lung cancer , 2004, International journal of cancer.

[12]  G. Bubley,et al.  Biology of prostate-specific antigen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Berkowitz,et al.  Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.

[14]  A. Görg,et al.  The current state of two‐dimensional electrophoresis with immobilized pH gradients , 2000, Electrophoresis.

[15]  Chih-Yi Chen,et al.  Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer. , 2002, Oncology reports.

[16]  Ignace Vergote,et al.  The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. , 2003, Cancer research.

[17]  N. Palackal,et al.  Activation of Polycyclic Aromatic Hydrocarbontrans-Dihydrodiol Proximate Carcinogens by Human Aldo-keto Reductase (AKR1C) Enzymes and Their Functional Overexpression in Human Lung Carcinoma (A549) Cells* , 2002, The Journal of Biological Chemistry.

[18]  N. Flamand,et al.  Androgen Formation and Metabolism in the Pulmonary Epithelial Cell Line A549: Expression of 17β-Hydroxysteroid Dehydrogenase Type 5 and 3α-Hydroxysteroid Dehydrogenase Type 3. , 2000, Endocrinology.

[19]  K. Kinzler,et al.  Identifying markers for pancreatic cancer by gene expression analysis. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Hanash,et al.  Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. , 2001, Cancer research.

[22]  H. Sasaki,et al.  Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. , 2001, Japanese journal of clinical oncology.

[23]  M. Seemann,et al.  An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions. , 1999, Lung cancer.

[24]  Pier Giorgio Righetti,et al.  Blue silver: A very sensitive colloidal Coomassie G‐250 staining for proteome analysis , 2004, Electrophoresis.

[25]  N. Bitterlich,et al.  Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer , 2002, International Journal of Clinical Oncology.

[26]  H. Albrecht,et al.  The Phosphatidylethanolamine-binding Protein Is the Prototype of a Novel Family of Serine Protease Inhibitors* , 2001, The Journal of Biological Chemistry.

[27]  J. Welsh,et al.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.